<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2009-677</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-814</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Этанерцепт (Энбрел) в лечении псориатического артрита</article-title><trans-title-group xml:lang="en"><trans-title>Etanercept (Enbrel) in the treatment of psoriatic arthritis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коротаева</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Korotaeva</surname><given-names>T V</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib></contrib-group><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>15</day><month>12</month><year>2009</year></pub-date><volume>47</volume><issue>6</issue><issue-title>№6 (2009)</issue-title><fpage>66</fpage><lpage>70</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Коротаева Т.В., 2009</copyright-statement><copyright-year>2009</copyright-year><copyright-holder xml:lang="ru">Коротаева Т.В.</copyright-holder><copyright-holder xml:lang="en">Korotaeva T.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/814">https://rsp.mediar-press.net/rsp/article/view/814</self-uri><abstract><p>Псориатический артрит (ПсА) – хроническое воспалительное заболевание суставов из группы серонегативных спондилоартритов, отличное от ревматоидного артрита (РА), тесно ассоциированное с псориазом. [1,2]. У большинства пациентов с ПсА развивается эрозивный олиго-полиартрит, нередко с признаками костной резорбции, спондилит, теносиновит, энтезит, у трети – дактилит (синоним – воспаление пальца), отсутствует ревматоидный фактор [3,4]. Дактилит обычно возникает в результате одновременного воспаления сухожилий и суставов пальца, клинически проявляется болью, гиперемией, плотным отеком всего пальца, считается прогностически неблагоприятным фактором в плане развития эрозий и остеолиза [5,6]. Кроме деструктивного артрита, другими аспектами неблагоприятного влияния ПсА является снижение качества жизни больных, а также повышение риска смерти от кардиоваскулярных заболеваний в 1,3 раза по сравнению с популяцией. Не исключено, что это связано с системным воспалением, которое возникает в результате дисбаланса про – и противовоспалительных цитокинов [7,8].</p></abstract></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">&lt;div&gt;&lt;p&gt;Patel S. Veale D., Fitzgerald O. et al. Psoriatic arthritis – emerging concepts. Rheumatol., 2001,40,243-6.&lt;/p&gt;&lt;p&gt;Ruderman E. M. Evaluation and management of psoriatic arthritis: the role of biological therapy. J Am Acad Dermatol., 2003,49 (suppl 2A),S125-32.&lt;/p&gt;&lt;p&gt;Khan M., Schentag C., Gladman D. D. Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol., 2003,30,1022-6.&lt;/p&gt;&lt;p&gt;Veale D., Rogers S., Fitzgerald O. Classification of subset in psoriatic arthritis. Br J Rheumatol., 1994,33,133-8.&lt;/p&gt;&lt;p&gt;Oliveri I., Barozzi L., Favaro L. et al. Dactilitis in patients with seronegative spondyloarthropathy. Assessment by ultrasonography and magnetic reso- nance imaging. Arthritis Rheum., 1996,39,1524–8.&lt;/p&gt;&lt;p&gt;Kane D., Greaney T., Bresnihan B. et al. Ultrasonography in the diagnosis and management of psoriatic dactilitis. J Rheumatol., 1999, 26,1746-51.&lt;/p&gt;&lt;p&gt;Hahn B. H, Grossman J., Chen W., McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslip- idemia. J Autoimmun., 2007, 28 (2-3), 69-75.&lt;/p&gt;&lt;p&gt;Peters M. J., v d Horst-Bruinsma I. E., Dijkmans B. et al. Cardiovascular risk profile of patients with Spondylarthropathies, particularly ankylosing spon- dylitis and psoriatic arthritis. Semin Arthritis Rheum., 2004,34,585-92.&lt;/p&gt;&lt;p&gt;Mease P. J. Psoriatic arthritis therapy advances. Curr Opin Rheum., 2005,4 (17), 426-32.&lt;/p&gt;&lt;p&gt;Mease P. I., Antoni C. E. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis., 2005,64 (Suppl 2),78-82.&lt;/p&gt;&lt;p&gt;Ritchlin C. Pathogenesis of рsoriatic аrthritis. Curr Opin Rheum., 2005,17,406-12.&lt;/p&gt;&lt;p&gt;Mease P. J. Tumor necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis., 2002, 61,298-304.&lt;/p&gt;&lt;p&gt;Kavanaugh A., Ritchlin C. and GRAPPA Treatment Guidelines Committee. Systematic review of treatments of psoriatic arthritis: an evidence based on approach and basis for treatment Guidelines. J Rheumatol., 2006,33(7),1417-21.&lt;/p&gt;&lt;p&gt;Kyle S., Chandler D., Griffiths C. E. et al. Guideline for anti-TNF-α in psoriatic arthritis. Rheumatol., 2005, 44, 390-7.&lt;/p&gt;&lt;p&gt;Tukriewicz A., Moreland L. Psoriatic Arthritis. Current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum., 2007,56(4),1051-66.&lt;/p&gt;&lt;p&gt;Gottlieb A., Korman N., Gordon K. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol., 2008,58(5),851-64.&lt;/p&gt;&lt;p&gt;Soriano E., McHugh N. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol., 2006, 33,1-9.&lt;/p&gt;&lt;p&gt;Salvarani C., Oliveri I., Pipitone N. et al. Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-α blocking) agents in the treatment in psoriatic arthritis of psoriatic arthritis. Clin Exp Rheum., 2006,24,70-8.&lt;/p&gt;&lt;p&gt;Ritchlin C. T., Kavanaugh A., Gladman D. D. et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis., pub. оnline 24 Oct 2008.&lt;/p&gt;&lt;p&gt;Antoni C., Kavanaugh A., Kirkhan B. et al. Sustained benefits of infliximab therapy for dermatological and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum., 2005,52, 1227-36.&lt;/p&gt;&lt;p&gt;Antoni C., Krueger G. G., de Vlam K. et al. IMPACT Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT Trial. Ann Rheum Dis., 2005, 64, 1150-7&lt;/p&gt;&lt;p&gt;Mease P., Gladman D., Ritchlin C. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum., 2005,52(10), 3279-89.&lt;/p&gt;&lt;p&gt;Gladman D., Mease P., Rithlin C. et al. Adalimumab improves joint- and skin-related functional impairment in patients with psoriatic arthritis: patients-reported outcomes of the adalimumab effectiveness in psoriatic arthritis trials (ADEPT). Ann Rheum Dis., 2006, 9, 1-6.&lt;/p&gt;&lt;p&gt;Scallon B., Cai A., Solowski N. et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther., 2002,301,418- 26.&lt;/p&gt;&lt;p&gt;Moreland L. W., Schiff M. H., Baumgartner S. W. et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med., 1999,130,478-86.&lt;/p&gt;&lt;p&gt;Mease P., Goffe B. S, Metz J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet, 2000,356,385-90&lt;/p&gt;&lt;p&gt;Mease P., Goffe B. S, Metz J. et al. Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis [Abstract]. Arthritis Rheum., 2000, 43(suppl),S403.&lt;/p&gt;&lt;p&gt;Mease P., Goffe B. S, Metz J. et al. Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis [Abstract]. Ann Rheum Dis.,2001, 60,146&lt;/p&gt;&lt;p&gt;Mease P., Kivitz A., Burch F. et al. Etanercept treatment of psoriatic arthritis. Safety, efficacy and effect on disease progression. Arthritis Rheum.,2004,50(7), 2264-72.&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation><mixed-citation xml:lang="en">&lt;div&gt;&lt;p&gt;Patel S. Veale D., Fitzgerald O. et al. Psoriatic arthritis – emerging concepts. Rheumatol., 2001,40,243-6.&lt;/p&gt;&lt;p&gt;Ruderman E. M. Evaluation and management of psoriatic arthritis: the role of biological therapy. J Am Acad Dermatol., 2003,49 (suppl 2A),S125-32.&lt;/p&gt;&lt;p&gt;Khan M., Schentag C., Gladman D. D. Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol., 2003,30,1022-6.&lt;/p&gt;&lt;p&gt;Veale D., Rogers S., Fitzgerald O. Classification of subset in psoriatic arthritis. Br J Rheumatol., 1994,33,133-8.&lt;/p&gt;&lt;p&gt;Oliveri I., Barozzi L., Favaro L. et al. Dactilitis in patients with seronegative spondyloarthropathy. Assessment by ultrasonography and magnetic reso- nance imaging. Arthritis Rheum., 1996,39,1524–8.&lt;/p&gt;&lt;p&gt;Kane D., Greaney T., Bresnihan B. et al. Ultrasonography in the diagnosis and management of psoriatic dactilitis. J Rheumatol., 1999, 26,1746-51.&lt;/p&gt;&lt;p&gt;Hahn B. H, Grossman J., Chen W., McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslip- idemia. J Autoimmun., 2007, 28 (2-3), 69-75.&lt;/p&gt;&lt;p&gt;Peters M. J., v d Horst-Bruinsma I. E., Dijkmans B. et al. Cardiovascular risk profile of patients with Spondylarthropathies, particularly ankylosing spon- dylitis and psoriatic arthritis. Semin Arthritis Rheum., 2004,34,585-92.&lt;/p&gt;&lt;p&gt;Mease P. J. Psoriatic arthritis therapy advances. Curr Opin Rheum., 2005,4 (17), 426-32.&lt;/p&gt;&lt;p&gt;Mease P. I., Antoni C. E. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis., 2005,64 (Suppl 2),78-82.&lt;/p&gt;&lt;p&gt;Ritchlin C. Pathogenesis of рsoriatic аrthritis. Curr Opin Rheum., 2005,17,406-12.&lt;/p&gt;&lt;p&gt;Mease P. J. Tumor necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis., 2002, 61,298-304.&lt;/p&gt;&lt;p&gt;Kavanaugh A., Ritchlin C. and GRAPPA Treatment Guidelines Committee. Systematic review of treatments of psoriatic arthritis: an evidence based on approach and basis for treatment Guidelines. J Rheumatol., 2006,33(7),1417-21.&lt;/p&gt;&lt;p&gt;Kyle S., Chandler D., Griffiths C. E. et al. Guideline for anti-TNF-α in psoriatic arthritis. Rheumatol., 2005, 44, 390-7.&lt;/p&gt;&lt;p&gt;Tukriewicz A., Moreland L. Psoriatic Arthritis. Current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum., 2007,56(4),1051-66.&lt;/p&gt;&lt;p&gt;Gottlieb A., Korman N., Gordon K. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol., 2008,58(5),851-64.&lt;/p&gt;&lt;p&gt;Soriano E., McHugh N. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol., 2006, 33,1-9.&lt;/p&gt;&lt;p&gt;Salvarani C., Oliveri I., Pipitone N. et al. Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-α blocking) agents in the treatment in psoriatic arthritis of psoriatic arthritis. Clin Exp Rheum., 2006,24,70-8.&lt;/p&gt;&lt;p&gt;Ritchlin C. T., Kavanaugh A., Gladman D. D. et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis., pub. оnline 24 Oct 2008.&lt;/p&gt;&lt;p&gt;Antoni C., Kavanaugh A., Kirkhan B. et al. Sustained benefits of infliximab therapy for dermatological and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum., 2005,52, 1227-36.&lt;/p&gt;&lt;p&gt;Antoni C., Krueger G. G., de Vlam K. et al. IMPACT Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT Trial. Ann Rheum Dis., 2005, 64, 1150-7&lt;/p&gt;&lt;p&gt;Mease P., Gladman D., Ritchlin C. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum., 2005,52(10), 3279-89.&lt;/p&gt;&lt;p&gt;Gladman D., Mease P., Rithlin C. et al. Adalimumab improves joint- and skin-related functional impairment in patients with psoriatic arthritis: patients-reported outcomes of the adalimumab effectiveness in psoriatic arthritis trials (ADEPT). Ann Rheum Dis., 2006, 9, 1-6.&lt;/p&gt;&lt;p&gt;Scallon B., Cai A., Solowski N. et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther., 2002,301,418- 26.&lt;/p&gt;&lt;p&gt;Moreland L. W., Schiff M. H., Baumgartner S. W. et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med., 1999,130,478-86.&lt;/p&gt;&lt;p&gt;Mease P., Goffe B. S, Metz J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet, 2000,356,385-90&lt;/p&gt;&lt;p&gt;Mease P., Goffe B. S, Metz J. et al. Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis [Abstract]. Arthritis Rheum., 2000, 43(suppl),S403.&lt;/p&gt;&lt;p&gt;Mease P., Goffe B. S, Metz J. et al. Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis [Abstract]. Ann Rheum Dis.,2001, 60,146&lt;/p&gt;&lt;p&gt;Mease P., Kivitz A., Burch F. et al. Etanercept treatment of psoriatic arthritis. Safety, efficacy and effect on disease progression. Arthritis Rheum.,2004,50(7), 2264-72.&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
